IRIX IRIDEX CORP
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1006045 · Fiscal year ends 01/03
Financial factors as of 2026-10-03 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY33.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-3.4%
Net income 3-yr CAGR—
Margins
Gross margin38.2%
Operating margin-5.1%
Net margin-6.9%
FCF margin-3.7%
EBITDA margin-4.2%
Returns
ROE-92.4%
ROA-11.7%
ROIC (approx.)—
Asset turnover1.71x
Leverage & solvency
Liabilities / assets91.0%
Debt / equity0.00x
Current ratio1.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.45x
Accruals ratio-6.5%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-10-03 | 2026Q22026-07-04 | 2026Q12026-04-04 | 2026Q4*2026-01-03 | 2025Q32025-09-27 | 2025Q22025-06-28 | 2025Q12025-03-29 | 2024Q4*2024-12-28 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $10.16M | $12.57M | $11.80M | $14.72M | $12.48M | $13.57M | $11.90M | $12.70M |
| Cost of revenue | $5.85M | $8.27M | $7.06M | $9.25M | $8.47M | $8.89M | $6.84M | $7.11M |
| Gross profit | $4.30M | $4.30M | $4.74M | $5.48M | $4.01M | $4.68M | $5.05M | $5.59M |
| R&D expense | $1.01M | $936,000 | $905,000 | $949,000 | $972,000 | $871,000 | $876,000 | $1.11M |
| SG&A expense | $2.04M | $1.84M | $1.62M | $1.79M | $1.79M | $2.22M | $1.93M | $2.27M |
| Operating income | -$1.16M | -$1.03M | -$324,000 | -$15,000 | -$1.41M | -$940,000 | -$205,000 | -$502,000 |
| Interest expense | — | — | — | — | — | — | — | $88,000 |
| Pretax income | -$1.32M | -$1.20M | -$466,000 | -$164,000 | -$1.57M | -$973,000 | -$1.67M | -$840,000 |
| Income tax | $78,000 | $70,000 | $58,000 | $20,000 | $4,000 | $21,000 | $12,000 | -$6,000 |
| Net income | -$1.40M | -$1.27M | -$524,000 | -$184,000 | -$1.57M | -$994,000 | -$1.69M | -$834,000 |
| EBITDA | -$1.04M | -$943,000 | -$224,000 | $136,000 | -$1.30M | -$813,000 | -$70,000 | -$367,000 |
| EPS (basic) | -0.08 | -0.07 | -0.03 | — | -0.09 | -0.06 | -0.10 | — |
| EPS (diluted) | -0.08 | -0.07 | -0.03 | — | -0.09 | -0.06 | -0.10 | — |
| Weighted avg. shares (diluted) | 17.59M | 17.42M | 17.31M | — | 17.01M | 16.79M | 16.73M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $3.67M | $4.68M | $4.59M | $6.03M | $5.57M | $6.78M | $7.24M | $2.39M |
| Receivables | $4.20M | $5.67M | $6.84M | $7.61M | $7.13M | $7.14M | $6.68M | $5.95M |
| Inventory | $11.76M | $9.75M | $9.32M | $7.88M | $7.30M | $8.44M | $10.14M | $10.82M |
| Current assets | $22.82M | $23.96M | $24.58M | $25.25M | $24.07M | $26.87M | $29.13M | $23.56M |
| PP&E, net | $210,000 | $182,000 | $139,000 | $58,000 | $23,000 | $40,000 | $75,000 | $115,000 |
| Goodwill | $965,000 | $965,000 | $965,000 | $965,000 | $965,000 | $965,000 | $965,000 | $965,000 |
| Intangibles | $745,000 | $825,000 | $904,000 | $984,000 | $1.06M | $1.14M | $1.22M | $1.31M |
| Total assets | $29.27M | $27.26M | $28.27M | $29.15M | $28.35M | $31.59M | $34.24M | $29.14M |
| Current liabilities | $12.99M | $13.17M | $12.83M | $13.21M | $12.39M | $13.71M | $14.95M | $16.56M |
| Short-term debt | — | — | — | — | — | — | — | $1.70M |
| Long-term debt | — | — | — | — | — | — | — | $1.00M |
| Total debt | — | — | — | — | — | — | — | $2.70M |
| Total liabilities | $26.64M | $23.62M | $23.54M | $24.23M | $23.67M | $25.53M | $27.38M | $27.04M |
| Shareholders' equity | $2.63M | $3.64M | $4.73M | $4.92M | $4.68M | $6.06M | $852,000 | $2.10M |
| Net debt | — | — | — | — | — | — | — | $313,000 |
| Shares outstanding | 17.81M | 17.45M | 17.40M | 17.31M | 17.05M | 16.81M | 16.79M | 16.64M |
| Cash flow statement | ||||||||
| Operating cash flow | -$942,000 | $174,000 | -$1.33M | $589,000 | -$1.16M | -$397,000 | -$1.15M | -$1.24M |
| Capital expenditure | $29,000 | $50,000 | $101,000 | $106,000 | $13,000 | $13,000 | $11,000 | $9,000 |
| Free cash flow | -$971,000 | $124,000 | -$1.44M | $483,000 | -$1.17M | -$410,000 | -$1.16M | -$1.25M |
| Investing cash flow | -$29,000 | -$50,000 | -$101,000 | -$106,000 | -$13,000 | -$13,000 | -$11,000 | -$9,000 |
| Financing cash flow | -$33,000 | -$38,000 | -$1,000 | -$27,000 | -$34,000 | -$14,000 | $6.04M | -$218,000 |
| Depreciation & amortization | $127,000 | $86,000 | $100,000 | $151,000 | $110,000 | $127,000 | $135,000 | $135,000 |
| Stock-based compensation | $182,000 | $212,000 | $211,000 | $213,000 | $92,000 | $257,000 | $213,000 | $316,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.